Can growing amounts of real-world MS data help clinicians predict disease progression and make more personalised treatment decisions?

In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Dr. Will Brown from Cambridge University and Dr. Carmen Tur from CEMCAT about the rapidly evolving field of predictive modelling in multiple sclerosis.

They explore why MS is particularly difficult to predict, from its biological and clinical heterogeneity to the lack of sufficiently sensitive, specific and widely available biomarkers. They also discuss how increasingly rich, long-term datasets are allowing researchers to study disease outcomes, treatment journeys and populations traditionally underrepresented in clinical trials.

The conversation examines the methodological challenges that come with real-world data, including missing data, non-random treatment allocation, clinical outcome selection and bias, as well as the opportunities and limitations of AI and machine learning.

Finally, they ask what must happen before predictive models can enter routine clinical care — including robust external validation, calibration, interpretability, equitable representation and evidence that using these tools actually improves clinical decisions and long-term patient outcomes.

---

This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Technology is opening new possibilities for how multiple sclerosis is monitored, treated and managed.

In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Ellen Mowry of Johns Hopkins University and Prof. Letizia Leocani of Vita-Salute San Raffaele University about how innovative medical technologies could transform MS research and clinical care.

Together, they explore:

• How artifical intelligence, wearable devices and digital biomarkers could help monitor MS progression
• The potential to capture fatigue, cognition, pain, mood, sleep and other symptoms between clinical visits
• How passive monitoring could provide a more complete picture of everyday life with MS
• The growing role of virtual rehabilitation, digital therapies and other technologies in bringing care into people's homes
• Why digital biomarkers require rigorous research and validation before being used in clinical trials

From earlier detection of disability progression to more accessible rehabilitation and personalised symptom management, this episode examines both the opportunities and challenges of using technology to improve MS care.

---

This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Could multiple sclerosis one day be detected before symptoms appear? And if so, should we be actively screening people who are at higher risk?

In this episode of the ECTRIMS–MS Journal collaboration series, host Prof. Anneke van der Walt, Controversies Editor at the Multiple Sclerosis Journal, is joined by Prof. Helen Tremlett (University of British Columbia) and Prof. Ruth Ann Marrie (Dalhousie University) to debate one of the most important emerging questions in MS research.

Helen argues that targeted screening should begin now—but only within carefully designed research studies—to better understand how MS develops before clinical symptoms appear. Ruth Ann argues that while prevention is the ultimate goal, the science, ethics and healthcare systems are not yet ready for widespread screening.

Together they discuss:

· Whether MS is entering a new era of prevention research

· What lessons can be learned from Parkinson's disease and radiologically isolated syndrome (RIS)

· The ethical and psychological impact of identifying people at risk before symptoms develop

· How screening programmes could improve—or worsen—health inequalities

· What research is still needed before screening could ever become part of routine clinical practice

Although they argue opposing positions, both experts agree on one important point: preventing MS is an achievable ambition—but only if research proceeds carefully, ethically and equitably.

This MS Journal Controversies article series has been made open access for the next month for ease of reading.

• "Yes" – High-risk populations should be screened for MS
• "No" – High-risk populations should not yet be screened for MS
• "Commentary" – High-risk populations should not yet be screened for MS

Note: This episode is part of the MS Journal Controversies in MS series, where experts debate opposing viewpoints on important unresolved questions in MS research. The positions argued do not necessarily represent the authors' personal opinions, but rather present the strongest evidence supporting each side of the debate.